Abstract : Cancer cells are subject to many apoptotic stimuli that would kill them were it not for compensatory prosurvival alterations. BCL‐2‐like (BCL‐2L) proteins contribute to such aberrant behaviour by engaging a network of interactions that is potent at promoting survival but that is also fragile: inhibition of a restricted number of interactions may suffice to trigger cancer cell death. Currently available and novel compounds that inhibit these interactions could be efficient therapeutic agents if this phenotype of BCL‐2L dependence was better understood at a molecular, cellular and systems level and if it could be diagnosed by relevant biomarkers.
https://www.hal.inserm.fr/inserm-02481124
Contributor : Philippe Paul Juin <>
Submitted on : Monday, February 17, 2020 - 11:51:49 AM Last modification on : Friday, June 19, 2020 - 3:08:56 AM Long-term archiving on: : Monday, May 18, 2020 - 2:56:30 PM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais